Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients

NCT01702090 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1

Interventions

DRUG: TMC114/ritonavir

Sponsor

Janssen-Cilag Ltd.